BioGaia AB (NASDAQ: BIOG) and Ewopharma AG have renewed their long-standing distribution partnership, reinforcing the companies’ successful collaboration and shared ambition to further expand the availability of BioGaia’s probiotic portfolio across Central Eastern Europe (CEE).
Under the renewed agreement, Ewopharma will continue to distribute a broad range of BioGaia products in more than 15 CEE countries, strengthening the companies’ joint efforts to make BioGaia’s probiotic products more widely available to consumers and healthcare professionals throughout the region.
“We are proud to continue our long-standing collaboration with BioGaia,” comments Alain Staub, CEO and President of the Board of Directors of Ewopharma. “Over the years, we have built a strong and trusted partnership based on a shared commitment to bringing innovative, science-based probiotic products to consumers and healthcare professionals across the region. We look forward to continuing to support the growth of the BioGaia brand throughout our markets.”
“We are very pleased to continue this partnership with Ewopharma,” adds Theresa Agnew, CEO and President of BioGaia. “Their deep knowledge of European markets, strong commercial capabilities, and well-established distribution network enable us to reach more consumers and healthcare professionals with our high-quality probiotic products. Ewopharma’s local expertise and commitment to our brand have been instrumental in driving our growth in Central Eastern Europe.”
About BioGaia AB
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. Further information is available at biogaiagroup.com.
Under the renewed agreement, Ewopharma will continue to distribute a broad range of BioGaia products in more than 15 CEE countries, strengthening the companies’ joint efforts to make BioGaia’s probiotic products more widely available to consumers and healthcare professionals throughout the region.
“We are proud to continue our long-standing collaboration with BioGaia,” comments Alain Staub, CEO and President of the Board of Directors of Ewopharma. “Over the years, we have built a strong and trusted partnership based on a shared commitment to bringing innovative, science-based probiotic products to consumers and healthcare professionals across the region. We look forward to continuing to support the growth of the BioGaia brand throughout our markets.”
“We are very pleased to continue this partnership with Ewopharma,” adds Theresa Agnew, CEO and President of BioGaia. “Their deep knowledge of European markets, strong commercial capabilities, and well-established distribution network enable us to reach more consumers and healthcare professionals with our high-quality probiotic products. Ewopharma’s local expertise and commitment to our brand have been instrumental in driving our growth in Central Eastern Europe.”
About BioGaia AB
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. Further information is available at biogaiagroup.com.
